PT - JOURNAL ARTICLE AU - Mundada, Nidhi S. AU - Rojas, Julio C. AU - Vandevrede, Lawren AU - Thijssen, Elisabeth H. AU - Iaccarino, Leonardo AU - Okoye, Obiora C. AU - Shankar, Ranjani AU - Soleimani-Meigooni, David N. AU - Lago, Argentina L. AU - Miller, Bruce L. AU - Teunissen, Charlotte E. AU - Heuer, Hillary AU - Rosen, Howie J. AU - Dage, Jeffrey L. AU - Jagust, William J. AU - Rabinovici, Gil D. AU - Boxer, Adam L. AU - La Joie, Renaud TI - Head-to-head comparison between plasma p-tau217 and Flortaucipir-PET in amyloid-positive patients with cognitive impairment AID - 10.1101/2022.11.29.22282851 DP - 2022 Jan 01 TA - medRxiv PG - 2022.11.29.22282851 4099 - http://medrxiv.org/content/early/2022/11/30/2022.11.29.22282851.short 4100 - http://medrxiv.org/content/early/2022/11/30/2022.11.29.22282851.full AB - Background and Objective Plasma phosphorylated tau (p-tau) has emerged as a promising biomarker for Alzheimer’s disease (AD). Studies have reported strong associations between p-tau and tau-PET that are mainly driven by differences between amyloid-positive and amyloid-negative patients. However, the relationship between p-tau and tau-PET is less characterized within cognitively impaired patients with a biomarker-supported diagnosis of AD. We conducted a head-to-head comparison between plasma p-tau217 and tau-PET in patients at the clinical stage of AD and further assessed their relationships with demographic, clinical, and biomarker variables.Methods We retrospectively included 87 amyloid-positive patients diagnosed with MCI or AD dementia who underwent structural MRI, amyloid-PET (11 C-PIB), tau-PET (18 F-flortaucipir, FTP), and blood draw assessments within one year (age=66±10, 48% female). Amyloid-PET was quantified in Centiloids (CL) while cortical tau-PET binding was measured using Standardized Uptake Value Ratios (SUVRs) referenced against inferior cerebellar cortex. Plasma p-tau217 concentrations were measured using an electrochemiluminescence-based assay on the Meso Scale Discovery platform. MRI-derived cortical volume was quantified with FreeSurfer. Mini-Mental State Examination (MMSE) scores were available at baseline (n=85) and follow-up visits (n=28; 1.5±0.7 years).Results Plasma p-tau217 and cortical FTP-SUVR were correlated (r=0.61, p<.001), especially in temporo-parietal and dorsolateral frontal cortices. Both higher p-tau217 and FTP-SUVR values were associated with younger age, female sex, and lower cortical volume, but not with APOE-ε4 carriership. PIB-PET centiloids were weakly correlated with FTP-SUVR (r=0.26, p=0.02), but not with p-tau217 (r=0.10, p=0.36). Regional PET-plasma associations varied with amyloid burden, with p-tau217 being more strongly associated with tau-PET in temporal cortex among patients with moderate amyloid-PET burden, and with tau-PET in primary cortices among patients with high amyloid-PET burden. Higher p-tau217 and FTP-SUVR values were independently associated with lower MMSE scores cross-sectionally, while only baseline FTP-SUVR predicted longitudinal MMSE decline when both biomarkers were included in the same model.Discussion Plasma p-tau217 and tau-PET are strongly correlated in amyloid-PET-positive patients with MCI and AD, and they exhibited comparable patterns of associations with demographic variables and with markers of downstream neurodegeneration.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe present study was supported by National Institutes of Health/National Institute of Aging grants NIH/NIA P30-AG062422 (to BLM, GDR), P01-AG019724 (to BLM), R01-AG045611 (to GDR), K99AG065501 (to RLJ) Rainwater Charitable Foundation (to GDR), Alzheimer's Association (to RLJ, AARF:16-443577 and DSM, AACSF:19-617663), NIH/NIA R35 -AG072362 (GDR), Alzheimer's Association ZEN-21-848216. NIH/NIA K23AG059888 (to JCR). NIH/NIA K23AG076960 (to DSM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Boards of University of California San Francisco, University of California Berkeley, and Lawrence Berkeley National Laboratory.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData that support the findings of this study are available upon request (memory.ucsf.edu/research-trials/professional/open-science). Voxelwise results are publicly available on neurovault (https://neurovault.org/collections/NLWHVBKP/). https://neurovault.org/collections/NLWHVBKP/